IMMUNE COMPLEX BINDING BY MODIFIED C-REACTIVE PROTEIN

免疫复合体(IC)是由抗体结合而成 带有抗原，这些抗原是传染性的成分 生物体，寄主生物体以外的其他分子，肿瘤- 相关分子，在许多疾病中，正常组织 分子成分。ICS从循环中移除，并 组织通过各种正常的机制。然而，他们的 自身免疫、恶性和传染性疾病的持续存在 疾病和组织中的沉积会导致 免疫系统功能和炎症病理。它是 该应用程序的长期目标是设计一种技术来 血液中ICs的体外清除是一种有效的方法 IC相关疾病的治疗模式。我们发现 一种正常人类蛋白质的修饰形式，在 对炎性刺激的反应，具有选择性地 绑定IC。这是最近和迄今为止未知的函数 分子。分子结合的特异性和有效性 TO IC将通过本研究中提出的研究来建立 应用：模型在体外形成的IC中，IC由 实验动物中的抗原诱导性IC疾病，以及ICs 在不同IC受累者的血清中 疾病。然后，这项技术将扩展到 临床试验用体外装置的研制。这个 IC结合蛋白用于ICs定量的可能性 也将进行探索。

Immune complexes (ICs) are formed by the binding of antibodies with antigens, the antigens being components of infectious organisms, other molecules foreign to the host organism, tumor- associated molecules, and in many diseases, normal tissue molecular components. ICs are removed from the circulation and tissues by a variety of normal mechanisms. However, their continued presence in autoimmune, malignant and infectious diseases, and deposition in tissues, contributes to compromised immune system function and inflammatory pathology. It is the long-term objective of this application to devise a technology for the extracorporeal removal of ICs from blood as an efficacious treatment modality for IC-involved diseases. We have discovered that a modified form of a normal human protein, elicited in response to inflammatory stimuli, has the ability to selectively bind ICs. This is a recent and heretofore unknown function of this molecule. The specificity and efficiency of the molecule's binding to ICs will be established by the research proposed in this application by using: model in vitro-formed ICs, ICs developed by antigen-induced IC disease in experimental animals, and with ICs in human sera derived from individuals with different IC-involved diseases. The technology will then be extended to the development of an extracorporeal device for clinical trails. The possible use of the IC-binding protein for the quantitation of ICs will also be explored.